XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Debt and Equity Securities - Equity Securities Transactions (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
shares
Sep. 30, 2021
USD ($)
shares
Aug. 31, 2021
Jul. 31, 2021
USD ($)
shares
Jun. 30, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Oct. 31, 2017
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2017
shares
Equity Securities                    
Net gains recognized on equity securities | $               $ 39,289 $ 105  
Impairment | $               762    
Preferred Stock                    
Equity Securities                    
Equity Securities without Readily Determinable Fair Value | $ $ 31,262         $ 16,071   $ 31,262 $ 16,071  
Astria/Catabasis | Common Stock                    
Equity Securities                    
Shares received in noncash transaction         259,206          
Shares issued upon conversion         3,580,539          
Reverse stock split ratio     0.166              
Number of shares               3,839,745    
Astria/Catabasis | Preferred Stock                    
Equity Securities                    
Shares received in noncash transaction       347 3,928          
Number of preferred stock converted (in shares)         3,581          
Equity Securities without Readily Determinable Fair Value | $ $ 312     $ 1,100 $ 12,100     $ 312    
Impairment | $               $ 800    
Technology License Agreement | MiRagen/Viridian                    
Equity Securities                    
Shares received in noncash transaction 394,737         322,407        
Purchase amount of share options or equity in noncash transaction | $ $ 7,500         $ 6,000        
Technology License Agreement | MiRagen/Viridian | Common Stock                    
Equity Securities                    
Shares received in noncash transaction 394,737         322,407        
Technology License Agreement | Astria/Catabasis | Common Stock                    
Equity Securities                    
Reverse stock split ratio     0.166              
License Agreement | INmune                    
Equity Securities                    
Shares received in noncash transaction             1,585,000      
Purchase amount of share options or equity in noncash transaction | $             $ 10,000      
Number of shares         192,533          
Cash consideration on sale of option | $         $ 15,000          
License Agreement | INmune | Common Stock                    
Equity Securities                    
Shares received in noncash transaction                   1,585,000
Additional equity interests (as a percentage)         10.00%         10.00%
Option to acquire shares             108,000     108,000
Shares issued upon conversion         192,533          
Purchase amount of share options or equity in noncash transaction | $   $ 800                
Net gains recognized on equity securities | $   $ 900                
Number of shares   108,000           1,885,533    
Cash consideration on sale of option | $         $ 15,000